Over the past two decades, proton magnetic resonance spectroscopy (proton MRS) of the brain has made the transition from research tool to a clinically useful modality. In this review, we first describe the localization methods currently used in MRS studies of the brain and discuss the technical and practical factors that determine the applicability of the methods to particular clinical studies. We also describe each of the resonances detected by localized solvent-suppressed proton MRS of the brain and discuss the metabolic and biochemical information that can be derived from an analysis of their concentrations. We discuss spectral quantitation and summarize the reproducibility of both single-voxel and multivoxel methods at 1.5 and 3-4 T. We have selected three clinical neurologic applications in which there has been a consensus as to the diagnostic value of MRS and summarize the information relevant to clinical applications. Finally, we speculate about some of the potential technical developments, either in progress or in the future, that may lead to improvements in the performance of proton MRS.
INTRODUCTION
Magnetic resonance imaging (MRI) has emerged as the pre-eminent imaging modality for visualizing neurologic diseases in the central nervous system. MRI can be used to produce both high-resolution anatomically-based images and images that reflect a variety of physiological parameters, including blood flow, tissue perfusion, and water mobility as reflected by diffusion indices. Magnetic resonance spectroscopy (MRS) is a complementary technique, providing metabolic information that can easily be integrated with MRI. The current version of MRS has, over the past five decades, evolved from a technique (originally known as nuclear magnetic resonance spectroscopy, or NMR spectroscopy) used in chemistry to determine the structure of molecules to a method with which to probe the metabolism of cells, tissues, intact animals, and humans. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Many of these applications involved acquiring 31 P spectra to assess the bioenergetics of the cells, tissues, or organs being studied. These studies required using additional radiofrequency (RF) hardware.
Although proton MRS was, and is, used extensively in chemical applications, its use in biological systems (in which the concentration of the compounds of interest are ϳ1-10 mmol/L) was hampered by the presence of a large background signal arising from water in the sample, which could have a concentration approaching 90 mol/L in protons. In the early days of MRS, this difference in signal amplitudes posed several problems (discussed later in this article), addressed by development of a variety of techniques that either did not excite the background water signal or suppressed it substantially. 14 -16 One of the major motivations for using proton NMR methods is the greater sensitivity of the nucleus ( 1 H), compared with either 31 P or 13 C. All other factors being equal, the MR sensitivity is proportional to the cube of magnetogyric ratio for each nucleus. This translates into relative sensitivities of ϳ10:1 for protons relative to 31 P and ϳ64:1 for protons relative to 13 C (at equal concentrations of compounds and isotopic enrichments). Notably, observing nuclei other than proton requires the development of RF coils and other specialized hardware tuned to their specific frequencies, whereas proton MRS uses the same hardware as standard MRI.
The first in vivo localized spectrum of rat brain acquired at 8.5 T in a vertical bore magnet was published by Behar et al. 17 in 1983 (FIG. 1) . The resonances were assigned with respect to spectra obtained on excised brain tissue and perchloric acid extracts of the brain tissue. Note that the major resonances assigned and the line-width of the lines obtained in vivo were significantly broader than those observed from either the intact tissue or extract. Behar et al. 17 also described the effects of cerebral hypoxia on the spectra (elevations in lactate), indicating the promise that proton MRS has for monitoring the metabolic consequences of various insults on the brain.
The first commercial whole-body 1.5 T MRI scanners (and slightly higher: 2.0 T) became available in the early 1980s. In 1985, Bottomley et al. 14 published the first human in vivo solvent-suppressed proton spectrum of the brain (FIG. 2) . Although most of the resonances found in rat brain are also observed, the lines are much broader, indicating that there are contributions from magnetic field inhomogeneities. This report was followed by two other articles showing similar results, one by Luyten and den Hollander 18 in 1986 and the other by Hanstock et al. 19 in 1988. In 1989, Frahm's group published a series of papers showing single-voxel MR spectra with much narrower lines, obtained using stimulated echoes 15, 16, 20 to localize to different regions of the brain. These exciting results began the modern era of proton MRS studies of the brain. Since the 1980s, there has been an increasing availability of whole-body MR scanners for use in diagnostic imaging. A large number of these MR scanners operate at magnetic fields of 1.5 T or higher, similar to the magnetic fields used in the early days of NMR spectroscopy. These scanners can perform localized proton MRS without additional hardware, provided that they have the capability for shimming (i.e., optimizing the field homogeneity).
The development of spatially localized MRS [21] [22] [23] [24] has provided a bridge between metabolism and the anatomic and physiological studies available from MRI. These can now be combined into a single MR examination. In cases where a distinct lesion or lesions are seen on MR, the MRS can provide metabolic profiles that might aid in the characterization of the lesion or lesions and their response to treatment. In cases where MRI reveals no distinct lesions, MRS can provide a noninvasive assessment of the underlying metabolic status of the tissue being studied. This is particularly important in diffuse pathologies, for which MRS may give insights into the patterns of disease evolution and progression.
Several recent reviews of proton MRS studies of the brain are available. [25] [26] [27] [28] Here, we will describe the localization methods currently used in MRS studies of the
FIG. 2.
Typical localized proton spectra from (a) human and (b) dog brain, both taken at 1.5 T and recorded using a slice-selective sequence (5 cm depth; 5 mm slice) using a 3-cm diameter coil. Abbreviations: AA, amino acids (glutamine, glutamate, and GABA); Cr, creatine; La, lactate; N-AcAsp, N-acetylaspartate; PCho, phosphoryl-choline; PCr, phosphocreatine. Reproduced with permission from Bottomley et al., 1985.
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FIG. 1.
The high-resolution proton NMR spectrum of rat brain: (A) extract; (B) intact tissue. Spectrum (C) was acquired in vivo on a wide-bore 360-MHz vertical bore system. Abbreviations: Cho, choline; Cr, creatine; lip, lipids; N-AcAsp, N-acetylaspartate; PCho, phosphocholine; PCr, phosphocreatine. Dashed lines indicate matching peaks across spectra. Reproduced with permission from Behar et al., 1983. 17 brain and discuss the technical and practical factors that determine the applicability of these methods to particular clinical studies. We will discuss each of the resonances detected by localized solvent-suppressed proton MRS of the brain in terms of the metabolic and biochemical information that can be derived from an analysis of their concentrations. We will then summarize the reproducibility of both single-voxel and multivoxel methods at 1.5 and 3-4 T and discuss the use of fields higher than 1.5 T. We will review clinical applications where there has been a consensus as to the diagnostic value of MRS. Finally, we will present some of the potential technical developments, either in progress or expected for the future, that may lead to improvements in the performance of MRS.
SPATIAL LOCALIZATION
Localization can be achieved in MRS by means of using RF gradients, static B 0 gradients, pulsed spatial gradients, or combinations of these. The technical details of these approaches have been described in detail. [21] [22] [23] [24] The combined RF and gradient methods are similar to those currently used in MRI. As already noted, the challenge in proton spectroscopy of metabolites is that metabolites at millimolar concentrations must be detected in the presence of a background water signal that is ϳ100 molar. For this reason, solvent-suppression techniques have been combined with localization schemes to produce spatially localized solvent-suppressed spectra. Both the T 1 and T 2 relaxation times of the various proton metabolites are quite long, permitting the use of methods such as spin-echo or stimulated-echo sequences.
For proton MRS of the brain, localization methods that either preserve the magnetization of only those protons being sampled and destroy the coherence of all of the unwanted spins, or pulse sequences wherein only the spins from the desirable locations are excited, or combinations of these two approaches, have found common use. The unwanted magnetization arises from several sources: the background water signal and the strong lipid signal arising from fat in the scalp. Regions with high magnetic susceptibility boundaries should be avoided in the excitation schemes.
Suppression of the water signal is usually accomplished by a 90°frequency selective excitation of the water followed by dephasing gradients. This process destroys all the magnetization components of the water (both the Z-magnetization and the XY magnetization). The efficiency of suppression depends on a number of factors, including the B 1 homogeneity of the 90°fre-quency selective excitation of the water (i.e., is this pulse a 90°pulse everywhere within the brain?) and the magnetic field homogeneity across the volume being sampled.
The two most commonly used localization methods, stimulated echo acquisition mode (STEAM) and point resolved spectroscopy (PRESS), select an orthorhombic volume in space by applying three sequential selective RF pulses in the presence of orthogonal slice-selective gradients. The STEAM sequence 15, 16 and PRESS 14 method can be implemented as single-voxel (i.e., sampling only one region of tissue) or multivoxel methods (selecting a larger orthorhombic volume combined with Fourier phase-encoding methods to produce both twodimensional and three-dimensional chemical shift imaging data-2D-CSI and 3D-CSI). [21] [22] [23] [24] Because both STEAM and PRESS excite the spins within the orthorhombic volume, these are examples of methods in which only those protons being sampled are excited and the other spins are either not excited or are destroyed. The advantages of using either of these two spatial preselection methods are that the signal from lipids arising from the scalp is minimized and the volume over which the B 0 field is adjusted can be restricted to avoid air-tissue boundaries, with their potential large variations in the magnetic susceptibility.
For reasons associated with instrument performance (e.g., residual eddy current effects), many of the early reports of proton MRS used echo delays of 135 or 270 ms. The choice of 135 or 270 ms is made to refocus the doublet resonance of the methyl resonance of lactate. As instrumental performance has improved, the greater emphasis has been placed on acquiring proton spectra at shorter echo times (TE) of 20 -60 ms. One advantage of these shorter delays is the ability to detect resonances from coupled spin systems (e.g., glutamate, glutamine, myo-inositol) whose apparent T 2 's are too short to permit detection at longer echo delays.
The STEAM sequence originally provided more precise localization because the slice profiles of the 90°p ulses were sharper than those achieved by conventional 180°refocusing pulses. 29, 30 The precision of spatial localization was improved in PRESS in two ways. First, the development of so-called digitally crafted or designer RF pulses has improved the quality of the slice profiles of the 180°pulses. [31] [32] [33] [34] [35] [36] [37] [38] [39] In addition, slice profiles have been improved through the use of a very selective spatial saturation pulse that can be applied at the six edges of the orthorhombus defined by either STEAM or PRESS spatial preselection. 40 In spite of these improvements, STEAM and PRESS may not be ideal methods for performing multivoxel studies of the brain. The requirement of selecting an orthorhombic volume means that major regions of the brain will not fit within this volume. These deficiencies have led investigators to use a variety of alternative methods to perform whole-brain MRS. One approach is to use spatial presaturation methods to destroy the magnetization from tissues close to air-tissue boundaries, where there may be large variations in the magnetic susceptibility. This method of spatial presaturation is often referred to as outer volume suppression (OVS). Other approaches that excite the full slice have used software techniques to remove spectral distortions arising from lipid resonances in the scalp. Both types of approach permit acquiring MRS spectra from regions of the brain that lie outside the orthorhombic volume defined using PRESS preselection.
Another potential problem with PRESS 3D-CSI methods is that the total acquisition time for 3D-CSI sequences can become quite long, because localization in all three dimensions is achieved by phase-encoding. To make scan times shorter and more manageable in clinical applications, most implementations of PRESS 3D-CSI methods use eight slice-encodes, which can result in relatively poor slice profiles. 21 A number of recent advances in both pulse sequence design and multireceiver (phased-array) RF coils can reduce acquisition times. For example, the spatial presaturation methods (OVS) can be combined with sliceinterleaved spin-echo sequences to provide multislice CSI acquisitions instead of the 3D-CSI methods based on PRESS selection. These multislice approaches have both shorter scan times (several interleaved slices per repetition time [TR] period) and improved slice profiles, compared with PRESS 3D-CSI. Also, these multislice methods can use dynamic shimming on each slice to improve the homogeneity relative to the PRESS-based sequences. Another approach is to use Hadamard encoding in the slice direction to improve slice profiles. 41, 42 The advantages and disadvantages of a variety of different approaches to whole-brain CSI have been discussed in detail by Barker and Lin 26 and Keevil. 24 A comparison of the performance of many of these CSI methods has been provided by Pohmann et al. 43 Barker and Lin 26 have an excellent discussion of methods that use multireceiver arrays (e.g., an eightchannel head array) to accelerate CSI acquisitions, similar to the methods used in parallel imaging. An added complication is that, although there have been descriptions of algorithms 44, 45 used in combining CSI spectra obtained from each individual coil element, few of these are routinely available on commercial whole-body clinical scanners. This situation is in contrast to multicoil MR imaging and parallel imaging, in which this combination (or acceleration, or both) is performed routinely. 46 In spite of the large number of choices that are available to investigators interested in 3D-CSI studies of the brain and their clear potential advantages over the PRESS family of methods, most whole-brain studies in the literature use PRESS-3D-CSI, probably because it is routinely available on most commercial MRS packages on whole-body scanners.
COMPOUNDS DETECTED BY MRS IN THE HUMAN BRAIN
Examples of proton MR spectra obtained from gray matter and white matter acquired using the PRESS sequence at 1.5 T with a TE of 35 ms are shown in Figure 3 . The most prominent resonances are labeled on these spectra. We will discuss each of these resonances (moving in turn from low to high parts-per-million values [ppm]). The biochemical basis for interpreting these spectra has been discussed in detail by Ross et al. 28 and Ross and Bluml. 47 We will briefly review these here.
FIG. 3.
Short-TE spectra of gray and white matter. Representative MR spectra acquired at 1.5 T at an echo delay of 35 ms using the PRESS sequence from (A) gray matter and (B) white matter. Abbreviations: AA, amino acids (glutamine, glutamate, and GABA); Cho, choline; Cr, creatine; mI, myo-inositol; NAA, N-acetylaspartate.
Lipid and lactate
Lactate is a doublet at 1.3 ppm. It is the end product of glycolysis. In general, lactate can become elevated in the brain in two ways. First, lactate will be produced if the tissue becomes ischemic. Second, it has been shown that lactate can become elevated if there are activated inflammatory cells present. Activated macrophages have been shown to produce high levels of lactate. 48 Lipids (0.9 and 1.3 ppm) can become elevated in some pathologic states. In general, most studies have avoided making any interpretations based on these resonances, because it is often unclear whether these peaks arise from out-of-voxel contamination (i.e., poor spatial localization).
N-Acetylaspartate
The isolation and identification of N-acetylaspartate (NAA) (2.0 ppm) in the brain of cats was reported by Tallan et al. 49 in 1956. Soon after the detection of NAA in proton MRS, Birken and Oldendorf 50 reviewed the literature regarding the role of NAA in brain biochemistry. In spite of more than 40 years of investigation, the role of NAA in the brain remains somewhat unclear. Simmons et al. 51 reported that NAA was found exclusively in neurons. This and many other observations have led many to conclude that NAA is a neuronal marker. This conclusion was questioned by Martin et al. 52 who reported MR spectra with little or no NAA in a three year-old patient with developmental deficits. This report was followed by several letters to the editor discussing the role of NAA as a neuronal marker. [53] [54] [55] There are approximately equal concentrations of NAA in white and gray matter, which raises the issue of whether NAA is a marker of axonal integrity as well. The utility of NAA as an axonal marker is supported by the loss of NAA in many white matter diseases, including leukodystrophies, multiple sclerosis (MS), and hypoxic encephalopathy. Because MS is thought to be a disease that affects axons, the level of NAA has been used to monitor axonal viability in white matter lesions of MS and in surrounding normal-appearing white matter.
Several groups have suggested that NAA is a cerebral osmolyte. 28,56 -59 This proposed role for NAA implies that NAA changes might be reversible, an observation that has been made in several human studies including MS, acquired immunodeficiency syndrome (AIDS), and temporal lobe epilepsy. 
Amino acids
Glutamine (Glu), glutamate (Gln), and GABA are labeled as amino acids (AA) (2.1-2.4 ppm) in the spectra (FIG. 3) . The determination of the individual concentrations of these compounds using 1 H MRS is hampered by the complex spectral appearance of Glu/Gln (Glx) due to J-coupling. Other metabolites also contribute to the signal at the chemical shift of Glu/Gln, which makes the accurate and precise determination of their concentrations difficult at 1.5 T. There are, however, indications that the use of higher field strengths can improve the quantitation of these compounds. 60 -64 Glutamate is of interest because it is the most abundant neurotransmitter in the brain, and Shulman's group 65, 66 estimated that the cycling between Gln and Glu accounts for more than 80% of cerebral glucose consumption. Recently, it has been shown that Glu is elevated in MS patients, in the MS lesions as well as in normally appearing white matter. 67 Elevations in Gln have been reported in patients with hepatic encephalopathy 68 -70 and Reye's syndrome. 71 Recently, Moore et al. 72 showed that the administration of topiramate increased brain Gln levels (detected at 4 T). This was interpreted as a consequence of topiramate positively modulating GABA A receptors. This finding is of interest because of the possible role for topiramate (not for) in the treatment of epilepsy, migraine headache, bipolar disorder, eating disorders, and alcohol dependence.
The detection and quantitation of GABA is of interest because there are a variety of drugs on the market that can, in principle, modulate GABA levels in the brain. Several groups have actively pursued the measurement of GABA, both at rest and under the modulation of a variety of agents. 70, [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] Note that all of these studies have been performed either at fields higher than 1.5 T or with special spectral editing sequences, or a combination of both.
Creatine
The neurobiochemistry of creatine (Cr) (3.0 ppm) has been discussed by Ross and Bluml. 47, 83 This resonance is made up of at least two compounds, Cr and phosphocreatine, that are in rapid chemical and enzymatic exchange. The total concentration of this compound is estimated to be 8.6 mmol/L in human brain. Many studies use the level of the Cr peak as an internal standard, because the levels of Cr are thought to be relatively constant across the brain and do not change in most pathologies. Caution is advised, however: in cases where there is tissue destruction, the level of Cr might fall. Also, there has been at least one report wherein a new human inborn error of Cr biosynthesis was manifested as an absence of cerebral Cr from the proton spectrum, a deficiency that was corrected by dietary administration of Cr. 84 
Choline
The biochemistry of the choline-containing compounds has been reviewed by Miller. 85 The choline (Cho) (3.2 ppm) resonance arises from the tetramethyl amine head group in soluble compounds such as Cho, phosphocholine, glycerophosphocholine, and betaine. From Figure 3 , it is clear that there are different levels of Cho in gray and white matter. Ross and Bluml 47 have reported that the concentration of Cho is ϳ1.6 mmol/L in white matter. There is also compelling evidence that glial cells have a high concentration of Cho. 86 -88 During active myelin breakdown, there is thought to be a release of phospholipids, leading to an increase of the Cho peak. 89 Increases in Cho due to inflammation have also been reported. 90, 91 These two observations may cause some overlap in interpreting results in lesions, such as tumefactive MS, [92] [93] [94] [95] that may have both inflammation and demyelination present.
Elevations in the Cho resonance in brain lesions have also been accepted as a sign of malignancy, 96 -103 which may add an additional level of nonspecificity to any interpretations made on the basis of this peak alone.
Myo-inositol
Myo-inositol (mI) (3.6 ppm) is a simple sugar that has a deceptively simple spectrum at 1.5 T. In the brain, mI is synthesized primarily in glial cells and cannot cross the blood-brain barrier. 104, 105 Myo-inositol is therefore considered to be a glial marker, and an increase in mI content is believed to represent glial proliferation or an increase in glial cell size. Because both processes may occur in brain inflammation, an increase in mI may be a surrogate marker for inflammation in the brain. Myoinositol has been suggested as a cerebral osmolyte since 1990. 106 Like Cho, mI has also been labeled as a breakdown product of myelin.
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QUANTITATION
Quantitation has been reviewed recently by Jansen et al. 108 There is still an ongoing debate on the merits concerning the relative versus absolute quantitation of the compounds detected by proton MRS in the brain.
One view is that only the determination of absolute concentrations is acceptable. This is based on the observation that the levels of all of the metabolites, including Cr, can change in brain pathologies. The calculation of absolute concentrations requires correction for many factors, including compartmentalization of compounds, correction for T 1 and T 2 relaxation effects, correction for excitation and reception profiles, determination of the actual rather than the prescribed volume sampled in both single-voxel and multivoxel studies, and referencing the results to a known internal or external standard. Several different approaches have been suggested for absolute quantitation. 109 -116 Most of these approaches make attempts to obtain estimates of the concentration of water and its compartmentalization in the brain volume (voxel) being sampled by spectroscopy. A common method involves fitting the T 2 decay curve of water in the voxel to several exponential decay curves in order to obtain estimates of the water in CSF and the concentration of water in various compartments of brain tissue in the volume being sampled. By referencing the relative area of the brain metabolite to the tissue water, one can, in principle, obtain estimates of its absolute concentration.
Critics of absolute quantification suggest that it may be impossible to correct for all of these factors, particularly in the presence of pathologic changes, without making potentially flawed assumptions. They therefore prefer to report relative concentrations, usually expressed as metabolite-to-Cr ratios. The potential flaw in this approach is that if the level of Cr is affected by the disease process, the use of the ratios themselves might be misleading.
The common step in either of these quantitation approaches is fitting the acquired spectra, to determine the area under each resonance. A number of approaches have been suggested for performing this step in the brain, and these various approaches applied to processing and fitting spectral data were recently reviewed in a series of articles devoted to spectral quantitation. [117] [118] [119] [120] One tool that appears to be gaining wide acceptance is LC-Model. We routinely use LC-Model to automatically fit CSI data sets obtained from the brain, using a version similar to that described by McLean et al. 121, 122 An example of the results of a fit of LC-Model to a brain spectrum obtained at 3 T from a normal volunteer is shown in Figure 4 . Note that the output of LC-Model includes both relative and absolute concentrations of the various compounds detected, as well as their standard deviations.
REPRODUCIBILITY OF MRS STUDIES OF NORMAL CONTROLS
The first report of a multisite trial of an automated, standardized, single-voxel, short TE (35 ms), PRESS brain MRS study performed at 1.5 T appeared in 1994. 123 A total of 131 spectra of 84 subjects at 11 sites gave ratios of NAA/Cr of 1.51 Ϯ 0.10; Cho/Cr of 0.87 Ϯ 0.10 and mI/Cr of 0.66 Ϯ 0.07. These spectra were acquired from a 2 ϫ 2 ϫ 2-cm voxel located in the right parietal region.
More recently, Venkatraman et al. 124 compared the precision (reproducibility) and variability of singlevoxel PRESS data collected from the anterior cingulate and hippocampus at 4.0 T with reproducibility (single subject scanned multiple times) [125] [126] [127] [128] [129] [130] [131] [132] [133] and variability studies (many subjects scanned at least once) 109,115,120,128 -130,134 -144 from the literature (many different regions of the brain). The motivation for the Venkatraman study was the review of Steen et al., 145 who found an average coefficient of variation (CV, % ϭ SD/mean ϫ 100) for NAA by Steen et al. 145 in the frontal lobe in healthy controls of 13.7% at 1.5 T (from 16 published studies). Venkatraman et al. 124 postulated that this CV could be reduced by acquiring the data at a higher field (i.e., 4 T).
Their review of the literature showed that there were little differences in the CVs of the major peaks (NAA, Cr and Cho) observed between STEAM (CV ϭ 6.0%) and PRESS (CV ϭ 7.4%) acquisitions. The average CVs for the variability studies (e.g., NAA ϭ 10.5%) were higher on average than those reported for the precision studies (NAA ϭ 5.4%), indicating that the biological variability might be important. The location of the single-voxel was important. For example, spectra obtained from the hippocampus showed the highest CVs (Ͼ12% on average).
The results reported by Venkatraman et al. 124 in their precision study also showed higher CVs in the hippocampus (13.9%) than in the anterior cingulate (9.2%) for the major metabolites. For mI, Glu, and GluϩGln (Glx), the average CVs were also appreciably higher in the hippocampus (21.2%) than in the anterior cingulate (15.3%). These authors also found higher average CVs in their variability study, compared with the precision study. The factors influencing these CVs were discussed in detail. We note that the CVs of the major metabolites at 4 T were not significantly lower than those reported at 1.5 T; however, the study at 4 T used the shortest acquisition time (4 minutes) and their volume of interest was among the smallest of the studies used in the comparisons. Both of these factors will influence the values of the CVs obtained for all of the metabolites.
Several studies were not included in the review by Venkatraman et al. 124 For example, Michael et al. 146 reported similar standard deviations to those found by Venkatraman et al. 124 for Glx measurements obtained at 1.5 T using short TE STEAM in the left prefrontal cortex. Hammen et al. 147 reported CVs ranging from 8.8% for NAA to 19.4% for GluϩGln in the hippocampus, acquired using short TE PRESS at 1.5 T. Wellard et al. 148 investigated the physiological variability in single-voxel short TE PRESS spectra at 3 T in the temporal and frontal lobes. They found the largest variability in measurements of Glu-Gln (29%) and in ml (28%). The variability in measurements of the major metabolites were similar to those described above. They concluded that the largest source of variability was caused by physiological variability rather than by instrumental factors.
Soreni et al. 149 examined the intraindividual variability in the striatum at 3 T using a short TE PRESS sequence. They found, in accord with previous studies, 150 -152 that there was an effect of laterality on the MR spectra. This laterality was interpreted in terms of voxel repositioning effects, rather than biological differences.
151 These authors found a higher level of NAA (but not Cr) in the afternoon than in the morning, within subjects. Two different hypotheses were offered for these differences. The first possible explanation is based on the fact that there is a known circadian variation of blood glucose levels. Also, there is coupling of NAA synthesis to glucose metabolism, leading to the possibility that the changes in NAA levels reflect indirectly the circadian variations in glucose. The second explanation is based on circadian variations in hydration. Because NAA has been shown to be involved in osmotic regulation, it is possible that alterations in brain hydration could lead to changes in NAA levels.
There have also been several reports on the reproducibility and reliability of CSI methods for brain studies. 127, [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] In general, the CVs of the metabolites were higher in the CSI studies than the single-voxel acquisitions. For example, Marshall et al. 155 reported CVs for NAA of ϳ20% at a TE of 25 ms at 1.5 T and ϳ12% for a TE of 145 ms. There was also a wide range of CVs for NAA reported across different regions of the brain. Maton et al. 159 reported 14 -20% changes in NAA, Cho and Cr on long TE PRESS studies of the hippocampus at 1.5 T. Recently, Inglese et al. 153 found the lowest CV for NAA at a TE of 288 ms regardless of what coil (singlechannel quadrature head coil versus eight-channel phased array) or field was used (1.5 T versus 3 T). This finding complicates planning studies, because resonances such as mI, Gln, GABA, and Glu cannot be detected at long TEs. In fact, Srinivasan et al. 154 have reported significant improvements in the measurement of mI at 3.0 versus 1.5 T at short TEs.
The statistical variabilities of the metabolite levels establish important benchmarks for comparing results between different patient groups, different field strengths, and different institutions. The potential effects of biological variation add another level of complexity to these kinds of comparisons. Finally, it is clear that there are a number of technical issues that still need to be addressed in a standardized way in order to improve the consistency of CSI results across patients and institutions.
IS PROTON MRS OF HUMAN BRAIN BETTER AT FIELDS HIGHER THAN 1.5 T?
MRS applications have always been drivers of moving to higher fields (for a review of high-field MRI and MRS, see Lenkinski 2006 165 ). This is based on experience with high-resolution NMR, for which the signal-to-noise ratio has improved with increasing field strength. By convention, in NMR and MRS, the signal-to-noise ratio is defined as peak amplitude divided by the root mean square of the noise level. It is well known that for biological samples in MRI the signal-to-noise ratio should scale linearly with the field. This is true as well for localized MRS, provided that the line-width of the resonance being detected does not increase with increasing field strength.
At present, there appears to be some confusion in the literature regarding the advantages of high field for proton MRS studies of human brain. The Minnesota group has shown excellent spectra from human brain at 7 T. 166 In these spectra, however, the line-width of the methyl resonance of Cr was found to be 9.5 Hz, compared with 5.5 Hz at 4 T. 166 As was the case in MR imaging, the line-widths at the higher fields have a significant contribution from diffusion of the metabolites through microscopic susceptibility gradients. This effect has been called dynamic susceptibility broadening, and it cannot be corrected by external shimming. In spite of the contribution of this dynamic susceptibility broadening to the line-widths of resonances at higher fields, shimming at the higher field is still crucial to the acquisition of highquality spectra.
Several investigators have shown that the signal-tonoise ratio gains at 3 T and 4 T are relatively modest compared with those predicted by theory. Bartha et al. 128 acquired multiple STEAM spectra (TE ϭ 20 ms, volume ϭ 8 cm 3 ) in a single individual at 1.5 T and 4 T, to compare the precision of metabolite quantification using automated software that incorporated field strength-specific prior knowledge. At 4 T, the signal-tonoise ratio based on peak height increased ϳ80%, and the line-widths increased ϳ50%. This signal-to-noise ratio increase improved the precision of quantification of metabolites by ϳ40%.
Barker et al. 167 compared single-voxel proton spectra of the human brain recorded in five subjects at both 1.5 T and 3.0 T, using the STEAM pulse sequence and data acquisition parameters that were closely matched between the two field strengths. Spectra recorded in the white matter of the centrum semiovale and in phantoms were compared in terms of resolution and signal-to-noise ratio. The values of T 2 were estimated at both field strengths. Spectra at 3 T demonstrated only a 20% improvement in sensitivity, compared to 1.5 T at short echo times (TE ϭ 20 ms). Although spectra in phantoms demonstrated significantly improved resolution at 3 T, compared with 1.5 T, the in vivo spectra showed almost a twofold increase in line-width at 3 T.
Based on a comparison of multivoxel studies at 1.5 and 3 T, Gonen et al. 168 showed that the expected gains in signal-to-noise ratio (23-46%) and spectral resolution were less than theoretically predicted; however, even these modest improvements led to more reliable peakarea estimations and an 1 H-MRS acquisition ϳ50% shorter at 3.0 versus 1.5 T. Li et al. 169 have shown why the gains at higher field are not as large as expected. Their explanation deals with the contribution of dynamic susceptibility broadening to the line-widths. In principle, decreasing the voxel size in the spectral acquisition may reduce the increase in line-width. This has been experimentally verified by Li et al. 169 Because the signal-tonoise ratio (as determined by the peak height) scales inversely with the line-width for a given peak area, these authors have pointed out that the signal-to-noise ratio decreases much less than expected as the voxel size is decreased. Thus, for higher field proton MRS, optimal signal-to-noise ratio gains may be achievable at smaller voxel sizes than are currently being used at 1.5 T.
As pointed out in the previous section, Srinivasan et al. 154 found that the reliability of determining the concentration of mI was significantly better at 3.0 T than at 1.5 T. They reported a relative improvement in signalto-noise ratio of 1.8 for mI at 3.0 T, compared with an improvement of 1.4 for the other metabolites. (Note that these studies were necessarily performed at short TE.)
Barker and Lin 26 have provided an excellent discussion of the effects of dynamic susceptibility broadening on the apparent T 2 of a given resonance. They point out that, although the real T 2 of a resonance such as that of NAA (measured with a CPMG sequence) does not change with field strength, the T 2 determined with a single spin echo becomes much shorter at higher fields, due to the effects of dynamic susceptibility broadening. Thus, Barker and Lin 26 recommend that MRS studies at higher field be performed at short echo delay. This short TE, however, will result in the detection of broad resonances in the baseline arising from so called macromolecular species. As a result, fitting programs such as LC-Model have been modified to include these resonances in spectral fitting approaches. Alternatively, macromolecular nulling approaches can be incorporated into the acquisition sequences to improve the baseline.
CLINICAL APPLICATIONS
In their recent review, Ross et al. 28 list and review the 12 most common uses for neurospectroscopy. We will focus on three of these areas (for more comprehensive reviews, see Gillard et al., 25 Lentz et al., 27 and Ross et al. 28 ), in which there have been replicable results reported from several institutions and there is a consensus that proton MRS has diagnostic value: Alzheimer's disease (AD), epilepsy, and adult brain tumors.
Alzheimer's disease
We have previously reviewed the application of proton MRS to study a variety of white matter diseases. 170 Here we summarize applications of proton MRS to AD, which have been reviewed recently by Mandal 171 and by Soher et al. 172 Historically, the definitive diagnosis of AD was made by pathologists at autopsy. MRI studies have attempted to show specific patterns of cerebral atrophy (primarily in the temporal lobe) in patients with a clinical diagnosis of AD. In 1993, Miller et al. 173 showed clear changes in MRS results in patients with AD. Their report has been followed by a host of other articles that have shown reproducible patterns of decreased NAA and increased mI in the occipital, temporal, parietal, and frontal regions of patients with AD, even at the early stages of the disease. 171, 172 These patterns of spectral alterations can be used to differentiate patients with suspected AD from normal elderly controls, as well as patients with other kinds of dementias. 174 These patterns, adapted from Kantarci et al., 174 are summarized in TABLE 1. These data were collected using a short echo PRESS sequence from a voxel positioned in the posterior cingulate gyri and inferior precunei. Note, that the discriminations were made on the basis of comparisons made pairwise using singlepeak ratios. Further improvements might be made by trying approaches such as linear discriminant analysis to separate the groups.
MRS has also been shown to be capable of diagnosing mild cognitive impairment (MCI), which has been recognized as a condition that can precede the development of AD. Moreover, MRS is capable of predicting which subjects with MCI will develop AD. [175] [176] [177] [178] This finding is of particular interest, given the increasing number of clinical trials aimed at evaluating the efficacy of different drugs in treating AD. The availability of a noninvasive method to monitor treatment response would be of enormous benefit in such studies.
Epilepsy
The application of proton MRS to study temporal lobe epilepsy was recently reviewed by Ross and Sachdev 179 and by Briellmann et al. 180 The report by Connelly et al. 181 in 1994 showed a mean reduction of 22% in the NAA signal, with a 15% increase in the Cr signal and a 25% increase in the Cho signal in the temporal lobes ipsilateral to the seizure focus, compared with normal controls. On the basis of the NAA/ChoϩCr ratio, correct lateralization was achieved in 15/18 cases. They concluded that proton MRS provided useful information in the preoperative investigation of patients with temporal lobe epilepsy, contributing to lateralization and detecting bilateral abnormalities, which was seen in more than 40% of the cases. Note that this study was performed at a TE of 135 ms, capable of observing only NAA, Cr, and Cho. The observation of reduced NAA and increased Cho has been replicated in numerous studies and by numerous groups. Moreover, at short TE, there is a consensus that there are increases in mI observed in the eliptogenic foci. 182 Several studies have found correlations between MRS alterations and the severity of disease. Hammen et al. 183 found a negative correlation between the frequency of interictal epileptiform discharges on EEG and NAA levels, and a positive correlation between the duration of seizure symptoms and Cr levels (at 1.5 T). These authors pointed out that, although the intrasubject variations in the NAA and Cr levels were too large to make confident evaluations on individual patients, there were prospects that further technical optimizations (i.e., higher field strength and improved spectral analysis) could make these evaluations possible.
Three earlier studies reported similar kinds of results. Garcia et al. 184 found that the level of NAA decreased with increased frequency of seizure in patients with temporal lobe or frontal lobe epilepsy. Serles et al. 185 found an inverse correlation between the frequency of spikes and the NAA/Cr ratio that approached statistical significance in patients with frontal lobe or temporal lobe epilepsy. Park et al. 186 found an inverse correlation between the NAA/Cr ratio and interictal epileptiform discharges in the contralateral focus of seizure, but not the ipsilateral focus. All of these studies indicate that there could be a role for MRS in evaluating the severity of epilepsy in individual patients.
Recently, several groups have addressed the potential for using MRS in preoperative studies for determining the laterality of the seizure focus (for a detailed metaanalysis of the literature from 1992-2003, see Willmann et al. 187 ). Historically, this has been the goal of many MRS studies of epilepsy. The development of established MRI protocols to visualize hippocampal alterations in epilepsy as a basis for identifying seizure focus has helped define three potential clinical uses for the combined MRI/MRS. First, the spectral alterations seen on MRS can be used to confirm the morphological changes seen on MRI. Second, in patients who show no obvious changes on MRI (ϳ30% of patients with temporal lobe epilepsy), MRS can identify the affected hemisphere in a majority of cases based on reductions in NAA and elevations in Cho (see recent results obtained at 1.5 T with a standard head coil, 188 and meta-analysis of the literature 187 ). Third, MRS can be used to predict good surgical outcomes, 187 because patients with an ipsilateral abnormality have a much better chance of a seizure-free outcome than patients with bilateral abnormalities.
Many of the studies have comments suggesting that the clinical efficacy of MRS will improve at higher fields and with multichannel receiver coils. Also, as was pointed out for AD, many of the results discussed here were made on the basis of the analysis of single-peak ratios or concentrations. Because the MRS abnormalities observed reflect alterations in multiple resonances (NAA, Cho, and others), more definitive statistical comparisons could result from applying approaches such as linear discriminant analysis or z-score analysis to take all of these changes into account.
Brain tumors
The use of proton MRS to study adult brain tumors has been reviewed in the literature. [101] [102] [103] The characteristic spectral features of brain tumors are elevations in Cho, elevations in lipid and lactate in necrotic regions, and reductions in NAA. Hollingworth et al. 189 recently reported the results of a systematic review of MRS for the characterization of brain tumors. This study examined the role of proton MRS in addressing five clinical questions: 1) distinguishing metastatic lesions from highgrade tumor; 2) high-grade versus low-grade tumor; 3) recurrent tumor versus radiation necrosis; 4) extent of tumor and, 5) tumor versus non-neoplastic lesions. The meta-analysis found that MRS could distinguish between high-grade and low-grade tumors (question 2). There is also a strong indication that MRS (in the context of an integrated MRI/MRS examination) can help in characterizing indeterminate brain lesions (question 5). MRS also shows promise in identifying the extent of tumor (question 4) and distinguishing recurrent tumor from radiation necrosis (question 3). The authors strongly suggested using standardized multisite trials to provide more widespread evidence for the use of MRS in addressing questions 3-5.
Besides assessing the efficacy of MRS in addressing these five questions, Hollingworth et al. 189 made eight recommendations about how future studies should be conducted and evaluated. One recommendation was that MRS studies should be evaluated either in terms of their incremental diagnostic value over standard-of-care MRI or on the basis of the overall diagnostic accuracy of the combination of MRI and MRS. The authors suggested that the article by Moller-Hartmann et al. 190 provides a good example to follow. They also recommended that, in addition to diagnostic accuracy, MRS should be evaluated in terms of its diagnostic impact. This point has been made for many other diagnostic tests where outcome studies are recommended, in addition to the more tradi-tional diagnostic accuracy paradigms. Finally, the costeffectiveness of MRS should be addressed, because this metric is of importance to health care providers and policy makers.
SUMMARY AND FUTURE DIRECTIONS
Proton MRS can detect a number of compounds that provide biochemical insight about the underlying metabolic basis for many diseases in the brain. Over the past two decades, a great deal of technical progress has been made in acquiring high-quality proton spectra of the brain. Over the past decade, the techniques for acquiring localized spectra have improved substantially.
There have been major improvements in extending MRS from single-voxel methods to multivoxel approaches. Most of the multivoxel methods are slice-selective 2D methods. Generalizing these methods to 3D whole-brain methods involves long acquisition times, which can be prone to artifacts. There are high-speed MRS imaging methods based on either echo-planar methods 191, 192 or spiral acquisitions. 193 These methods are capable of acquiring spectral data in relatively short scan times, but are usually acquired at relatively high bandwidths, which may limit their signal-to-noise ratios. The use of these methods at higher field strengths (e.g., 3 T or 4 T), with multicoil arrays, or in a combination of both may overcome some of these deficiencies.
Progress has also been made in providing computerbased methods for analyzing these spectra. One result of this progress has been the determination of the reproducibility of MRS in normal controls across various brain regions, localization methods, and field strengths. Another result has been the emergence of meta-analysis of the efficacy of MRS in several pathologies (some of which have been discussed here). As a result, it is now possible to begin to define clinical areas where MRS has proven diagnostic efficacy and to define other promising areas of MRS in which multisite clinical trials could be initiated.
In spite of the technical progress, there are still gaps in the understanding of the biochemistry of each of the compounds detected in the spectra. For example, the precise function of NAA is not completely understood, as is evidenced by the debates about its role as a neuronal marker. Also, the roles of the cholines and mI in the brain need further investigations. Defining the biochemical roles for all of these compounds could be fruitful areas of research in the future.
Although several groups have examined the levels of Glu, Gln, and GABA, these approaches have not gained much traction in the community. This situation may change with the increasing availability of high-field scanners (3-7 T) and the development of localized multispectral dimensional MRS methods, such as 2D-COSY. 194 -196 These methods are particularly useful for identifying and detecting spin-coupled resonances such as Glu, Gln, and GABA. Although they require rather long acquisitions in their conventional implementations, recent advances in high-speed methods may make these techniques practical for application in humans. [197] [198] [199] [200] [201] [202] Although the focus here has been on proton MRS methods, several recent advances may make 13 C MRS feasible for human studies. These all center around the concept of 13 C hyperpolarization, which has been pioneered by the group headed by Golman. [203] [204] [205] [206] [207] [208] [209] Using these techniques, signal-to-noise ratio enhancements of more than 10,000:1 have been achieved in vitro. Historically, many metabolic pathways have been probed using either 14 C or (more recently) 11 C as radiolabels. It has also been shown that 13 C MRS studies using enriched 13 C have enormous potential for probing metabolic pathways. The advantages of 13 C methods lie in the fact that MR methods can detect the metabolic products of the administered labeled compound, whereas radiotracer studies follow only the tracer. A main disadvantage is the poor signal-to-noise ratio of the method, even at 100% enrichment. Hyperpolarization, however, may overcome this disadvantage.
In summary, over the past two decades proton MRS of the brain has benefited from technical improvements. Standardization in both spectral acquisitions and their analysis has occurred, primarily in single-voxel methods but also, more slowly, in multivoxel approaches. The availability of higher field scanners and multicoils will both accelerate MRS applications and increase the need for further assessment, validation, and standardization. There are several areas where proton MRS has already proven diagnostic efficacy. The number of these can be expected to only increase over time. One of the next major challenges will be to understand how to extract the maximum amount of clinically useful information from MRS spectra and how to optimally make use of this information, often in combination with other MR-based methods, to affect patient management.
